Evaluating Deucravacitinib for Juvenile Psoriatic Arthritis in Children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the levels, efficacy, and safety of Deucravacitinib (BMS-986165) in children diagnosed with juvenile psoriatic arthritis. Participants must have at least three affected joints and have previously tried other medications without success. The study involves administering either Deucravacitinib or a placebo to assess its impact on the condition. The goal is to determine how well the drug works and its safety profile in a pediatric population.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
* Participants must have at least three joints that are affected by arthritis.
* Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.

Exclusion Criteria

* Participants must not have been diagnosed with JPsA before 5 years of age.
* Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
* Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's running

• Centro de Oncologia Leonardo Da Vinci - ATO Terapias
  Fortaleza, Ceará, Brazil Recruiting
• Santa Casa de Misericordia de Belo Horizonte
  Belo Horizonte, Minas Gerais, Brazil Recruiting
• Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância
  Curitiba, Paraná, Brazil Recruiting
• Hospital Das Clinicas Ufpe
  Recife, Pernambuco, Brazil Recruiting
• LMK Serviços Médicos S/S
  Porto Alegre, Rio Grande do Sul, Brazil Recruiting
• Hospital Lifeplus Litoral Norte
  Xangri-lá, Rio Grande do Sul, Brazil Recruiting

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Deucravacitinib for scarring hair loss (frontal fibrosing and central centrifugal alopecia)

  This trial will test whether taking deucravacitinib once daily for 48 weeks helps adults with frontal fibrosing alopecia or central centrifugal cicatricial alopecia.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07508488

• Deucravacitinib added to current PsA treatment for difficult-to-control disease

  This study tests whether adding deucravacitinib to a patient’s existing Psoriatic Arthritis treatment can improve symptoms and quality of life for adults with hard-to-control disease.

  Recruiting Phase 4 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07280702

• Long-term safety of deucravacitinib versus ustekinumab for plaque psoriasis (PRAGMATYK)

  This study will test whether deucravacitinib or ustekinumab has better long-term safety for adults with moderate-to-severe plaque psoriasis who have cardiovascular risk factors.

  Recruiting at 323 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 410 other locations · NCT07116967

• Deucravacitinib safety during pregnancy.

  This project will see if taking deucravacitinib during pregnancy affects pregnancy and baby outcomes for people with psoriasis.

  Recruiting Bristol-Myers Squibb · La Jolla, California · NCT07017699

• Deucravacitinib for teens with moderate to severe plaque psoriasis

  This trial will test whether deucravacitinib helps teens with moderate to severe plaque psoriasis while tracking safety and drug levels.

  Recruiting at 89 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 132 other locations · NCT06979453

• Continued deucravacitinib treatment for people with systemic or cutaneous lupus who completed earlier trials

  This open-label extension lets people with systemic lupus or discoid/subacute cutaneous lupus who finished specific earlier trials continue taking deucravacitinib to see if ongoing treatment remains safe and tolerable.

  Recruiting at 2 sites Phase 4 Bristol-Myers Squibb · Farmington, Connecticut and 3 other locations · NCT06875960

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.